Opendata, web and dolomites

CardioProtectMI SIGNED

A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CardioProtectMI project word cloud

Explore the words cloud of the CardioProtectMI project. It provides you a very rough idea of what is the project "CardioProtectMI" about.

consequence    serious    mitigate    causing    tissues    emerged    safety    recommend    disease    deaths    medium    survival    market    anti    drug    clinical    damage    efficacy    infarction    tissue    alone    reported    inflammatory    date    mi    utmost    therapeutics    procedure    trials    cell    class    resolution    blood       stages    later    death    humans    business    10    guidelines    company    drugs    generation    effect    supporting    itself    positioning    rate    myocardial    incidence    provider    reveal    ihd    severe    innovation    candidate    12    inflammation    52    therapeutic    plan    flow    treatments    validation    ischaemic    therapies    chronic    pharma    decreases    injury    protective    restoration    14    heart    smei    improvement    strategic    prepare    stakeholders    models    aps    cardio    opportunity    prove    stopping    first    congestive    million    acute    ensuing    mortality    failed    therapy    strategies    peptide    human    400    animal    biotechnology    resother    readiness    reperfusion    engage   

Project "CardioProtectMI" data sheet

The following table provides information about the project.

Coordinator
RESOTHER PHARMA APS 

Organization address
address: DRONNINGGARDS ALLE 136
city: KOBENHAVN
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESOTHER PHARMA APS DK (KOBENHAVN) coordinator 50˙000.00

Map

 Project objective

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOPROTECTMI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIOPROTECTMI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More